Caxton Associates LP United Therapeutics Corp Transaction History

Caxton Associates LP

  • $3.12 Billion
  • Q4 2024

A detailed history of Caxton Associates LP transactions in United Therapeutics Corp stock. As of the latest transaction made, Caxton Associates LP holds 1,402 shares of UTHR stock, worth $502,210. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,402
Previous 4,686 70.08%
Holding current value
$502,210
Previous $1.68 Million 70.58%
% of portfolio
0.02%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$348.66 - $410.0 $1.14 Million - $1.35 Million
-3,284 Reduced 70.08%
1,402 $494,000
Q3 2024

Nov 14, 2024
SELL
$311.04 - $363.55 $1.45 Million - $1.7 Million
-4,666 Reduced 49.89%
4,686 $1.68 Million
Q2 2024

Aug 14, 2024
BUY
$228.26 - $319.04 $2.13 Million - $2.98 Million
9,352 New
9,352 $2.98 Million
Q4 2023

Feb 14, 2024
BUY
$214.88 - $256.94 $6.24 Million - $7.47 Million
29,059 Added 3088.1%
30,000 $6.6 Million
Q3 2023

Nov 14, 2023
BUY
$211.82 - $248.24 $199,322 - $233,593
941 New
941 $212,000
Q3 2020

Nov 16, 2020
SELL
$99.9 - $121.13 $700,598 - $849,484
-7,013 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$92.74 - $125.82 $650,385 - $882,375
7,013 New
7,013 $849,000
Q1 2020

May 15, 2020
SELL
$79.39 - $115.35 $360,509 - $523,804
-4,541 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$78.31 - $95.34 $164,372 - $200,118
-2,099 Reduced 31.61%
4,541 $400,000
Q3 2019

Nov 14, 2019
BUY
$74.85 - $85.99 $497,003 - $570,973
6,640 New
6,640 $530,000
Q3 2017

Nov 14, 2017
SELL
$114.6 - $136.81 $320,880 - $383,068
-2,800 Closed
0 $0
Q2 2017

Aug 29, 2017
BUY
N/A
2,800
2,800 $363,000

Others Institutions Holding UTHR

# of Institutions
723
Shares Held
60.9M
Call Options Held
123K
Put Options Held
104K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.3B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email